January 31, 2012

Elanco acquires bioscience firm ChemGen

Elanco has bought ChemGen Corp., a privately held bioscience firm specialising in the development and commercialisation of modern feed enzyme products that enhance poultry, egg, and meat production efficiency.

The acquisition will provide Elanco, the animal health division of Eli Lilly and Company, with a portfolio of leading feed enzyme products, as well as a pipeline of innovative compounds in development.

ChemGen will continue research and administrative operations at its current location in Gaithersburg, Maryland, US and manufacturing activities at its facility in Terre Haute, Indiana, as well as its present sales and field service operations.

Upon closing of the transaction, ChemGen will become a wholly owned subsidiary of Lilly and an operating unit of Elanco.

The transaction is expected to close in the first quarter of 2012, contingent upon clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act and other customary closing conditions. Financial terms of the transaction were not disclosed.